Fatostatin hydrobromide has been used:
- to study its anti-cancer activity and effects on mitotic microtubule spindle
- to study its effects on stomatal development
- to prevent SREBP cleavage-activating protein (SCAP)-mediated escort of sterol regulatory element-binding proteins (SREBPs)
Fatostatin A is an inhibitor of sterol regulatory element binding protein (SREBP). Fatostatin A reverses hyperglycemia in diabetic mice. Cell permeable. Fatostatin A is used for the treatment and/or prevention of one or more metabolic disorders.
Fatostatin is a non-sterol diarylthiazole derivative. It prevents insulin-induced adipogenesis and lowers the amounts of fatty acid, triglyceride and low-density lipoprotein. Fatostatin has anti tumor and antimitotic properties.
fatostatin a is an inhibitor of sterol regulatory element binding protein (srebp), which can inhibit the activation of srebp-1 and srebp-2[1].fatostatin a (0.1-1 μm; 3 days) inhibits the androgen-independent proliferation of prostate cancer cell in a manner independent of the known igf1 signaling pathway. fatostatin a inhibits insulin-induced fat formation in 3t3-l1 cells[2].fatostatin a (30 mg/kg; 150 ml; i.p.; daily for 28 days) prevents obese ob/ob mice from increasing their weight, blood sugar, and liver fat accumulation, even if they do not control the food intake of mice[1].[1]. kamisuki s, et al. a small molecule that blocks fat synthesis by inhibiting the activation of srebp. chem biol. 2009, 16(8): 882-92.[2]. choi y, et al. identification of bioactive molecules by adipogenesis profiling of organic compounds. j biol chem. 2003, 278(9): 7320-4.
Fatostatin hydrobromide is an SREBP inhibitor. Fatostatin hydrobromide inhibits fat production and lowers glucose levels in mice by inhibiting SREBP (Sterol Regulatory Element Binding Proteins).
